Nomenclature {#nom0005}
============

α-13\'-OH

:   α-13\'-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyl-tridecanol

α-13\'-COOH

:   α-13\'-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyl-tridecanoic acid

α-CEHC

:   α-carboxyethyl-hydroxychroman

α-LCM

:   α-tocopherol long-chain metabolites

α-SCM

:   α-tocopherol short-chain metabolites

α-TOH

:   α-tocopherol

COX

:   cyclooxygenase

CYP3A4

:   cytochrome P450, subfamily IIIA, polypeptide 4

CYP4F2

:   cytochrome P450, subfamily IVF, polypeptide 2

LDL

:   low density lipoprotein

oxLDL

:   oxidized low density lipoprotein

Introduction {#s0005}
============

Atherosclerosis is a progressive inflammatory disease characterized by excessive deposition of cholesterol in the arterial wall. Despite intensive therapeutic treatment opportunities the atherosclerotic complications are still the leading cause of death in Western industrialized countries.

Leonardo da Vinci (1452--1519) was probably the first who described the macroscopic changes of atherosclerosis, when he illustrated the lesions in arteries obtained from an elderly man at autopsy. His visionary idea was that the pathological thickening of the arterial wall was due to 'excessive nourishment' from the blood. Many decades later da Vinci׳s observation was studied in more detail by Carl von Rokitansky (1852) and Rudolf L. K. Virchow (1821--1902). In 1856 Virchow proposed that injury of the endothelium may initiate the disease process of atherosclerosis. Based on this idea, Russell Ross (1929--1999) and John A. Glomset came up in 1973 with the 'response-to-injury' hypothesis which is still generally accepted today in the form of the more generalized concept of endothelial dysfunction as the initial cause of atherosclerosis.

The pioneering work of Virchow and Nikolai N. Anitschkow (1885--1964) provided first evidence for the importance of the deposition of lipids from the blood, in particular cholesterol, in the arterial wall. Their findings formed the basis for the lipid hypothesis which connects plasma cholesterol levels to the development of the disease. In 1951, G. Lyman Duff (1904--1956) and Gardner C. McMillan (1918--2004) formulated the lipid hypothesis in its modern form, which is, despite controversial discussions, still widely accepted today. Since the discovery of the importance of the cholesterol contained in low-density lipoprotein (LDL[2](#fn2){ref-type="fn"}) particles for the pathogenesis of atherosclerosis, the concept of endothelial dysfunction has become tightly linked to the lipid hypothesis.

Almost 30 years ago the concept originated from work by Daniel Steinberg and Joseph L. Witztum that oxidative stress and the oxidation of LDL particles might contribute to atherosclerosis. The idea came up from the observation that the incubation of macrophages with oxidized LDL (oxLDL[3](#fn3){ref-type="fn"}) but not with native LDL led to the intracellular accumulation of cholesteryl esters. The idea that oxidative stress is involved in atherogenesis gained much attention and created tremendous excitement to look for oxLDL *in vivo* as well as for different kinds of oxidized lipid species within the particle. Since oxLDL appears in human plasma as well as within the arterial wall it was even a small step to the idea that supplementation with antioxidants may prevent atherosclerosis by inhibiting the formation of oxLDL. This hypothesis appeared to be on solid ground due to epidemiological evidence and the success in several animal studies using a variety of antioxidants. The euphoria of initial success led to clinical trials to validate the hypothesis and natural antioxidants were of particular interest as the expectation was that these natural compounds would have less undesirable effects. Accordingly a number of clinical trials were performed using, for example, vitamin E, which surprisingly have not been overwhelmingly supportive of the hypothesis. An overview on the controversial findings for vitamin E obtained from clinical trials is given in [Fig. 1](#f0005){ref-type="fig"}.

In this review, we want to summarize the controversial role of vitamin E as a preventive agent against atherosclerosis and to point the attention to recent findings by our group that highlight a role of long-chain metabolites of vitamin E as a proposed new class of regulatory metabolites and to their potential contribution to atherosclerotic processes.

Pathogenesis of atherosclerosis {#s0010}
-------------------------------

The endothelium covering the arterial walls comprises a physiological and selective barrier, the so-called intima, between blood and the inner layer of the arterial wall. This so-called media is comprised by contractile smooth muscle cells. Pathophysiological stimuli cause endothelial dysfunction triggering inflammatory processes in the vascular wall which result under chronic conditions in extensive morphological changes characterized by intimal thickening, deposition of cholesterol and fibrotic material, loss of elasticity, reduction of vascular lumen, and widening of the vessel diameter [@bib1]. Endothelial dysfunction is thought to be caused by exogenous stimuli, such as environmental factors (e.g., toxicants such as dioxins, PCBs, and pesticides), unhealthy lifestyle (e.g., smoking and physical inactivity) and dietary habits (e.g., high intake of saturated fat). The impact of exogenous factors depends on endogenous local and systemic conditions. Local factors are vessel-associated junctions, bifurcations and curvatures which are responsible for increased shear stress caused by turbulences of the blood stream in these areas, which are thus predestinated for the formation of atherosclerotic lesions [@bib2]. Pro-atherogenic systemic factors are determined either genetically or pathophysiologically, for example, in case of increased LDL and triglyceride plasma levels [@bib3; @bib4] as well as inflammatory conditions [@bib5]. The process of atherosclerosis is outlined and explained in more detail in [Fig. 2](#f0010){ref-type="fig"}.

A key event of atherogenesis is the loss of the selective endothelial barrier by endothelial dysfunction which allows, for example, LDL to enter the arterial wall. Once inside the vessel wall, LDL particles become prone to oxidation. The oxidized particles cause damage to the tissue thus triggering a cascade of immune and inflammatory responses. In addition, macrophages, the phagocytic cells of the immune system, are recruited to the affected tissue sites to clear the oxLDL particles. As a consequence oxidized lipids and particularly cholesterol accumulate within the macrophages as these cells are not able to process the oxLDL completely. This causes transformation of the cells into so-called foam cells and ultimately cell death as the excessive accumulation of intracellular lipids is cytotoxic. Death of macrophage foam cells results over time in the extracellular deposition of cholesterol in the arterial wall and the formation of an atheroma. The process of atherosclerosis is outlined and explained in more detail in [Fig. 2](#f0010){ref-type="fig"}.

Thus, vitamin E was considered as an anti-atherogenic agent for a long time as prevention of LDL oxidation by providing increased levels of antioxidants would prevent the formation of macrophage foam cells and atheroma, and would dampen the immune and inflammatory response.

Effects of α-Tocopherol on atherogenic processes {#s0015}
------------------------------------------------

Vitamin E is likely the most important lipid antioxidant in the human diet. The term vitamin E comprises a group of eight abundant isomers (α-, β-, γ-, δ-tocopherol and -tocotrienol), that differ by their methylation patterns of the hydroxychromanol ring and saturation of the side-chain. Many *in vitro* studies have been performed with α-tocopherol (α-TOH[4](#fn4){ref-type="fn"}) which is the most active isomer within the group of vitamin E [@bib6]. *α*-Tocopherol exhibits anti-oxidative capacity *in vitro* [@bib7], and it has been shown to particularly inhibit, for example, the oxidation of LDL. Beside this, α-TOH shows anti-inflammatory features by, for example, inhibiting cyclooxygenase (COX[5](#fn5){ref-type="fn"}) 2. Next to its anti-inflammatory and anti-oxidative properties, the vitamin E isomers may have a variety of further independent properties, namely the modulation of gene expression, particularly that of genes encoding proteins involved in signaling but also the uptake, transport and degradation of tocopherols, as well as the uptake of lipoproteins and the storage and export of lipids such as cholesterol. The *in vitro* and *ex vivo* effects of α-tocopherol on cellular processes are depicted in [Fig. 3](#f0015){ref-type="fig"}.

α-Tocopherol metabolites and their bioactivity {#s0020}
----------------------------------------------

Metabolic degradation of α-TOH takes place almost exclusively in the liver. Beside metabolites resulting from oxidation of the chroman moiety, hepatic metabolism of α-TOH involves CYP3A4[6](#fn6){ref-type="fn"}-dependent ω-hydroxylation and α-oxidation, which results in the formation of the *α*-tocopherol long-chain metabolites (α-LCM[7](#fn7){ref-type="fn"}) α-13\'-OH[8](#fn8){ref-type="fn"} (13\'-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyl-tridecanol) and α-13\'-COOH[9](#fn9){ref-type="fn"} (13\'-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyl-tridecanoic acid), and further steps of β-oxidation, which results in the formation of middle- and short-chain metabolites (α-SCM[10](#fn10){ref-type="fn"}) with the catabolic end-product α-carboxyethyl-hydroxychroman (α-CEHC[11](#fn11){ref-type="fn"}), respectively [@bib8; @bib9; @bib10]. The short-chain metabolites are excreted via urine and are often used as a marker for α-TOH supply [@bib11]. Other tocopherols, such as γ- and δ-tocopherol, are almost quantitatively degraded and excreted via the urine as the corresponding γ- and δ-CEHCs. The hepatic metabolism of α-TOH is illustrated in [Fig. 4](#f0020){ref-type="fig"}.

Regulatory activity is not restricted to α-TOH as its short-chain metabolite α-CEHC also exhibits bioactivity. It has been shown that α-CEHC is anti-proliferative [@bib12], anti-inflammatory [@bib13], and anti-oxidative [@bib14], and inhibits oxLDL formation [@bib15] and protein kinase C (PKC[12](#fn12){ref-type="fn"}) signaling [@bib16]. Recently, researchers focused also on investigating the cellular effects of the α-LCM as α-13\'-COOH was detected in human serum, a finding providing clear evidence for its systemic bioavailability. Until now, only a few cellular effects of the α-LCM have been described, such as pro-apoptotic, anti-proliferative and anti-inflammatory features [@bib17; @bib18; @bib19; @bib20], which are highlighted in [Fig. 4](#f0020){ref-type="fig"}. A recent study by our group showed that α-LCM also affect macrophage foam cell formation by regulating uptake of oxLDL by macrophages via down-regulation of its phagocytic uptake ([Fig. 4](#f0020){ref-type="fig"}) [@bib17]. A key finding of our study was that bioactivity of the α-LCMs occurs at much lower concentrations and with mechanisms distinct from those of their metabolic precursor α-TOH.

Perspective {#s0025}
-----------

The findings obtained from clinical trials with humans raise the question whether vitamin E *in vivo* exhibits modes of action different from those found *in vitro*. Recent studies shed new light on mechanistic aspects of α-TOH function, which appear to be complicated by α-LCM circulating in the blood. We speculate that the α-LCM represent a new class of regulatory metabolites and propose that unraveling the molecular modes of action of the α-LCM and identifying the key players involved in their signaling may provide new fundamental insights into the biology and mode of function of vitamin E. Further studies are therefore required to elucidate the physiological role of the α-LCM and their contribution to disease processes, such as atherosclerosis. We also hypothesize that the discrepancy between the results obtained *in vitro* and *in vivo* in humans may be due to the physiologic metabolism of α-TOH and the formation of α-LCM in the liver and their release into circulation.
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LDL, low density lipoprotein.

oxLDL, oxidized low density lipoprotein.

α-TOH, α-tocopherol.

COX, cyclooxygenase.

CYP3A4, cytochrome P450, subfamily IIIA, polypeptide 4.

α-LCM, α-tocopherol long-chain metabolite(s).

α-13\'-OH, α-13\'-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyl-tridecanol.

α-13\'-COOH, α-13\'-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyl-tridecanoic acid.

α-SCM, α-tocopherol short-chain metabolite(s).

α-CEHC, α-carboxyethyl-hydroxychroman.

PKC, protein kinase C.

![Effects of α-TOH *in vivo*. Many *in vitro* investigations (A) focused on the identification of α-TOH-regulated signaling pathways and its effects on inflammation, lipid homeostasis, atherosclerotic plaque stability as well as xenobiotic metabolism as key processes. Taken together most of the *in vitro* studies implicated that vitamin E, and particularly α-TOH, may be used to prevent or cure cardiovascular disease (CVD) and related diseases, such as atherosclerosis. Based on very promising studies *in vitro* and with animals several large-scaled human intervention trials were initiated and followed up over years. Unfortunately, the trials revealed controversial results and failed to demonstrate clear invers relations or positive effects of α-TOH supplementation with respect to the prevention of cardiovascular complications [@bib21] (B). Further, α-TOH serum levels did not correlate with cardiovascular outcomes in different cohorts. Although some studies reported promising findings, such as the 'Nurses' Health Study (NHS) [@bib22] including 87,000 volunteers in which vitamin E supplementation was associated with a lower risk of major coronary disease, other large-scale studies, such as the Heart Outcomes Prevention Evaluation (HOPE) study [@bib23], the SU.VI.MAX study [@bib24], the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) study [@bib25] did not confirm that vitamin E intake correlates negatively with cardiovascular outcomes. Other studies revealed also contrary results depending on the time of follow-up and the cardiovascular parameter investigated or they showed unclear results (for example, the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) [@bib26; @bib27; @bib28; @bib29; @bib30], the Physicians׳ Health Study [@bib31], the Health Professionals Follow-up Study (HPFS) [@bib32; @bib33]). In a recent meta-analysis Ye et al. also found no significant inverse correlation for CVD and cardiovascular mortality under vitamin E [@bib34]. Reasons for the poor outcomes of clinical trials are hardly to define. Beside a general failure of vitamin E, other reasons may explain the lack of any cardio-preventive effect. Likely the selection of volunteers, the sizes of cohorts, doses and duration of supplementation or rather the application form of vitamin E with respect to its bioavailability, the food questionnaires and variability of food intake may explain the findings. Furthermore, it cannot be excluded that the interaction of vitamin E with other food ingredients contributes to the lack of its cardio-preventive activity. From a technical point of view, it cannot be excluded that vitamin E in stored sample is chemically modified or degraded so that frozen biological samples are not completely comparable to fresh samples. Another important point refers to the fact that most of the intervention trials concentrated on secondary prevention in patients with already existing CVD. It has been suggested that vitamin E supplementation may be more effectively for inhibiting the early stages of atherosclerosis [@bib35] and should be considered for primary prevention, as recently supported by Meydani et al. emphasizing the beneficial effects of long-term vitamin E supplementation in Ldlr^−/−^ mice under healthy life-style conditions, such as low fat diet [@bib36]. However, this hypothesis has not yet been confirmed. In summary (C), there is no clear evidence that supplementation with vitamin E correlates inversely with CVD incidence. Meta-analyses of observation studies suggest that vitamin E intake may prevent CVD and cardiovascular events [@bib37; @bib38; @bib39]. Knekt et al. performed a pooled analysis of observation studies with dietary vitamin E intake and supplementation in separate arms and found a significant inverse correlation of intake and CVD events only in the supplementation group [@bib40]. Apart from that meta-analysis of intervention studies provide evidence that supplementation with vitamin E does not reduce CVD incidence [@bib38; @bib41; @bib42; @bib43]. There are several drawbacks of meta-analysis that should be considered while interpreting these results, such as combination of heterogeneous data sets (regarding quality, statistics and focus within the topic), publication bias as well as criteria for inclusion and exclusion of the meta-analysis. However, it cannot yet be excluded that vitamin E intake is protective at least in some groups of humans against CVD as primary prevention. It is also important to remind that Miller et al. focused in their meta-analysis on some intervention studies, which provided evidence for an increase in all-cause mortality after supplementation with high doses of vitamin E [@bib44]. These findings in humans raise the question whether α-TOH *in vivo* exhibits modes of action different from those found *in vitro.* Possible explanations for the inability of vitamin E to prevent CVD and its complications in clinical trials in humans have been outlined above and are summarized in (D). Abbreviations and references: Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) [@bib26; @bib27; @bib28; @bib29; @bib30], Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) [@bib45], Austria [@bib46], Cambridge Heart Antioxidant Study (CHAOS) [@bib47], Cancer Prevention Study II (CPS-II) [@bib48], Costa Rica [@bib49], Czech Republic [@bib50], Eastern Finland Heart Surveys [@bib51], Epidemiologic Study of Cardiovascular Risk Indicators (EPOZ Study) [@bib52], Established Populations for Epidemiologic Studies of the Elderly (EPESE) [@bib53], Finnish Mobile Clinic Examination Survey (FMC) [@bib54], Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI) [@bib25], HDL-Atherosclerosis Treatment Study (HATS) [@bib55], Health Check-up Program (CHEP) [@bib56], Heart Outcomes Prevention Evaluation Study (HOPE) [@bib23], HOPE-The Ongoing Outcomes \[HOPE-TOO\] [@bib57], Iowa Women׳s Health Study (IWHS) [@bib58], Japan [@bib59], Lixian dysplasia trial (LIXIAN-2) [@bib60; @bib61], Medical Research Council/British Heart Foundation (MRC/BHF) [@bib62], Multinational MONItoring of trends and determinants in CArdiovascular disease (MONICA) [@bib63], Noninstitutionalized Massachusetts Residents (NMR) [@bib64], Physicians׳ Health Study (PHS) [@bib31], Physicians׳ Health Study II (PHS-II) [@bib65], Rotterdam Study [@bib66], Scotland and UK [@bib67], Scottish Heart Health Study (SHHS) [@bib68], Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) [@bib69], Shanghai Survey [@bib70], South African [@bib71], South of India [@bib72], Supplémentation en Vitamines et Minéraux Antioxydants (SU.VI.MAX) [@bib24], Tehran [@bib73], The Health Professionals Follow-up Study (HPFS) [@bib32; @bib33], The Multiple Risk Factor Intervention Trial (MRFIT) [@bib74], The Nurses׳ Health Study (NHS) [@bib22], The Primary Prevention Project (PPP) [@bib75], The Zutphen Study (ZS) [@bib76], Tunisian [@bib77], UK [@bib78], Women׳s Antioxidant Cardiovascular Study (WACS) [@bib79], Women׳s Health Study (WHS) [@bib80], 9 countries [@bib81]. The name of countries/cities refers to the countries/cities in which the studies have been performed, if no name for the studies is available.](gr1){#f0005}

![Key events of atherogenesis. Atherosclerosis is a complex and progressive inflammatory disease characterized by extensive morphological changes of the vascular wall. The arterial wall is composed of the *intima*, formed by endothelial cells (EC), the *media*, comprised of smooth muscle cells (SMC), and the *adventitia*, made of fibroblasts. The intermediate layers of the arterial vessel are the *lamina elastica interna*, connecting the *intima* with the *media*, and the *lamina elastica externa*, the connection between the *media* and the *adventitia*. Key changes of the vascular wall during the progression of atherosclerosis are intimal thickening, extensive extracellular deposition of cholesterol and fibrotic material, loss of elasticity, reduction of the vascular lumen and widening of the arterial diameter [@bib1]. Endothelial dysfunction is caused by exogenous and endogenous noxes and is the initial event in atherosclerosis. The dysfunction of the endothelium is accompanied by up-regulation of adhesion molecules in EC, which promote attachment and recruitment of T-lymphocytes and monocytes from the blood (I) and initiate immigration of monocytes into the subendothelial area of the vessel wall (IIa). Migration of monocytes, T-lymphocytes and SMC from the *media* (IIb) finally results in intimal thickening and fibrosis. Following migration of monocytes through the *intima*, differentiation of these cells into macrophages occurs (III). Macrophages as the phagocytic cells of the immune system play a pivotal role in the progression of atherosclerosis. They actively engage by taking up lipids from oxLDL in a non-controlled manner, by storing large amounts of cholesteryl esters, and by mobilizing cholesterol for reverse cholesterol transport [@bib82; @bib83]. Macrophages also orchestrate the inflammatory process, are responsible for the immigration of SMC from the *media* by releasing chemotactic molecules and proteases, and modulate the fibrotic process. LDL particles diffuse from the blood into the subendothelial space as a consequence of the loss of the endothelial barrier during endothelial dysfunction (IV). In the arterial wall the lipids and LDL are subjected to oxidation and enzymatic modification. The resulting oxLDL is taken up by macrophages (V) via scavenger receptors and phagocytosis in uncontrolled fashion [@bib84]. Recent studies have also highlighted the intra-plaque proliferation of macrophages in the lipid-rich stage of atherosclerotic plaque development (VI) [@bib85]. Accumulation and uptake of oxLDL by macrophages triggers the secretion of chemotactic molecules [@bib86], which promote the migration of SMC from the *media* into the subendothelial tissue. The intimal SMC lose their ability to contract, proliferate and synthesize extracellular matrix which results in fibrosis as part of the plaque development. The deposition of the extracellular matrix leads to further accumulation of oxLDL and lipids, in particular cholesterol and cholesteryl esters. The uptake of oxLDL via scavenger receptors is not subjected to negative feedback regulation, thus resulting in excessive intracellular lipid accumulation and formation of macrophage foam cells (VII) [@bib87], as well as the release of chemotactic mediators. During further progression of atherosclerosis, fatty streaks are formed and the thickening of the vascular wall progresses through the ongoing deposition of extracellular lipids and proliferation of intimal SMC, and the accompanied synthesis of extracellular matrix proteins. Over many years these processes together form the characteristic necrotic lipid core covered and stabilized by a fibrotic cap (VIII). The stability of the atherosclerotic plaque is defined by the amount of accumulated lipids and also by the amount and quality of the extracellular matrix of the fibrotic cap; the progressing accumulation of lipids is often accompanied by reduced stability of the fibrotic cap (IX). Weakening of the cap may finally result in rupturing of the plaque, particularly in areas rich in macrophages as these cells produce a broad range of proteases that degrade the extracellular matrix of the fibrotic cap [@bib88; @bib89]. Plaque rupture causes thrombus formation (X) via the activation of the coagulation cascade [@bib87]. Thrombi may occlude the artery at the site of plaque rupture or may flow through the blood stream and occlude downstream arteries that have a smaller lumen. In some cases, thrombi at the plaque site are reorganized and integrated into the plaque. This finally leads to the formation of the so-called complicated plaque (not shown).](gr2){#f0010}

![Atherosclerosis-relevant *in vitro* and *ex vivo* effects of α-tocopherol. Due to its function as an antioxidant, vitamin E was considered to interfere with key events in atherogenesis. To gain better insights into the contribution of vitamin E to the molecular processes underlying the hallmarks of atherosclerosis much effort was spend on *in vitro* and *ex vivo* experiments as well as studies involving animal models. As the complex pathogenesis of atherosclerosis involves several different cell types, the figure is divided according to the cells of interest (EC, SMC, monocytes and macrophages, hepatocytes) as well as non-cellular, plaque-specific processes and categories such as lipid homeostasis, signaling, inflammation, plaque stability and xenobiotic metabolism which are used to reflect the hallmarks of atherosclerosis. Endothelial cells surface the arterial wall and their dysfunction is the initial step of atherogenesis. α-Tocopherol reduces the stimulus-induced expression of adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1) and E-selectin [@bib90; @bib91; @bib92], and decreases thereby the adhesion [@bib92] and immigration of leukocytes [@bib93] onto the endothelium or into the arterial wall, respectively. α-Tocopherol makes it easier for EC to deal with oxidative stress, such as H~2~O~2~-induced lipid peroxidation [@bib7], due to higher catalase expression [@bib94], increased H~2~O~2~ degradation activity, and higher intracellular GSH levels [@bib13]. Thus, apoptosis of EC induced by oxidative stress is reduced [@bib95]. Beside reducing the release of inflammatory cytokines, such as interleukin (IL) 8 [@bib96], in response to external stimuli, α-TOH interferes with cellular signaling by inhibiting, for example, PKC [@bib97], activate nuclear factor κB (NFκB) [@bib98] or binding of peroxisome proliferator-activated receptor γ (PPARγ) to its regulatory DNA elements [@bib94]. Lipid homeostasis of SMC is also affected by α-TOH, for example by down-regulation of the scavenger receptor CD36 leading to reduced uptake of oxLDL [@bib99]. α-Tocopherol inhibits migration [@bib100] and proliferation of SMC by inhibiting PKC [@bib101], and prevents 7-ketocholesterol-induced apoptosis [@bib102]. Plaque stability is modulated by connective tissue growth factor (CTGF), which stimulates the synthesis of extracellular matrix. This factor is induced by α-TOH in SMC [@bib103], suggesting that α-TOH contributes to plaque stability by inducing fibrotic processes. Several signaling cascades in SMC are also modulated by α-TOH, namely PKC [@bib104; @bib105], extracellular signal-regulated kinase (ERK) [@bib106], protein kinase B (PK/AKT) and protein phosphatase 2A [@bib107]. Monocytes migrate in the arterial wall, differentiate into macrophages and transform to foam cells under atherogenic conditions. α-Tocopherol reduces adhesion and migration of leukocytes by down-regulating expression of CD11b [@bib93] and very late antigen-4 (VLA-4) [@bib92; @bib108]. Macrophage foam cell formation is prevented by reducing the expression of scavenger receptors CD36 [@bib109; @bib110] and A [@bib111]. On the other hand, foam cell formation is triggered by the down-regulation of the lipid exporters ATP-binding cassette transporter (ABC) A1 and G1 [@bib110]. Furthermore, the inflammatory response of macrophages to stimuli such as lipopolysaccharide (LPS) is dampened. The diminished induction of COX2 and inducible nitric oxide synthase (iNOS) by α-TOH results in a reduced release of prostaglandin E~2~ (PGE~2~) and nitric oxide [@bib112; @bib113]. The release of pro-inflammatory cytokines such as IL-1b, IL-6, tumor necrosis factor α (TNFα), and interferon γ (IFNγ) is also reduced [@bib113]. Similar to SMC, 7-ketocholesterol-induced apoptosis is reduced by α-TOH in macrophages [@bib114; @bib115]. Signaling pathways, such as NFκB [@bib108] and oxLDL or lipid-free high density lipoprotein induced liver X receptor α (LXRα) activity, are also inhibited by α-TOH [@bib110]. The liver is the major organ for cholesterol biosynthesis and metabolism of lipoproteins, xenobiotics and α-TOH. In liver cells α-TOH down-regulates expression of CD36 [@bib116; @bib117] and the LDL receptor [@bib118], as well as expression of enzymes involved in cholesterol biosynthesis, such as HMG-CoA reductase and HMG-CoA synthase [@bib118]. In contrast, expression of cytochrome P450 subfamily 27A polypeptide 1 (CYP27A1), and thus synthesis of 27-hydroxycholesterol, is induced by α-TOH [@bib119]. Similar to the situation in macrophages, activation of NFκB and expression of iNOS in response to stimuli is reduced by α-TOH [@bib120]. α-Tocopherol also induces CYP3A11 to levels which might interfere with drug metabolism [@bib121]. In addition to the effects of α-TOH on the different cell types involved in atherogenesis, α-TOH improves plaque stability in hyperlipidemic rabbits. Treatment of the animals with α-TOH increased the number of plaques with thicker, stabilizing fibrotic caps and reduced necrotic lipid core areas as well as reduced number of ruptured plaques [@bib122]. Formation of oxLDL was also blocked by α-TOH [@bib123]. Several studies using animals such as hypercholesterolemic rabbits or mice suggest that vitamin E inhibits atherogenesis in early [@bib124] or advanced stages by its antioxidant capacity [@bib125] or gene regulatory potential via signal transduction cascades and on adhesion molecules [@bib126; @bib127]. While high dose supplementation of vitamin E can improve myocardial tolerance to ischemia and reperfusion [@bib128], Keaney et al. found that low dose α-TOH improves and high dose worsens endothelial vasodilatory function in cholesterol-fed rabbits [@bib129]. Under extreme conditions, such as pronounced elevation in systemic oxidative stress due to hyperlipidaemia and obesity, vitamin E seems to be not cardioprotective [@bib130].](gr3){#f0015}

![α**-**Tocopherol metabolism and *in vitro* characteristics of its liver-derived long-chain metabolites. Due to the antioxidant capacity of vitamin E, early studies on its metabolism have concentrated on metabolites resulting from oxidation of the chroman moiety. The major oxidation product in the liver was described as α-tocopheryl quinone. This metabolite derives from the reaction of the tocopheroxyl radical with a peroxyl radical; it can be reduced to α-tocopheryl hydroquinone by NAD(P)H-dependent microsomal and mitochondrial enzymes. For many years, the so-called Simon metabolites, α-tocopheronic acid and its lactone, were the only known urinary α-TOH metabolites. The Simon metabolites are characterized by the opened chroman ring. Opening of the chroman ring starts with the formation of an α-tocopheroxyl radical when α-TOH has exerted its antioxidant activity. The Simon metabolites were therefore considered as urinary indicators that α-TOH had reacted as an antioxidant [@bib131]. Today some researcher rise the question whether Simon metabolites are artefacts produced during sample preparation as α-CEHC is easily converted to α-tocopheronolactone by oxygenation [@bib10; @bib132]. α-Tocopherol is physiologically catabolized in the liver via the xenobiotic detoxification system involving CYP3A4 [@bib8] and CYP4F2[@bib133]. Cytochrome-dependent *ω*-hydroxylation results in the formation of the long-chain alcohol derivate α-13\'-OH, 13\'-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyl-tridecanol. Subsequent α-oxidation leads to α-13\'-COOH, 13\'-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyl-tridecanoic acid. The following β-oxidation steps in peroxisomes and mitochondria form the α-SCM, α-carboxyethyl-hydroxychroman (α-CEHC) [@bib6]. This end-product of α-TOH metabolism can be conjugated and is excreted via urine [@bib134]. The intact chroman structure indicates that α-CEHC is derived from α-TOH that has not reacted as an antioxidant. As α-CEHC excretion increases when certain plasma levels of *RRR*-α-TOH are exceeded, excretion of α-CEHC is considered as an indicator of adequate or excessive α-TOH supply. Although hepatic metabolism of α-TOH and the formation of the metabolic long- and short-chain intermediates are known for several years [@bib8; @bib9; @bib10], the physiological function of the α-LCM α-13\'-OH and α-13\'-COOH is still unknown. Due to a lack of the pure compounds α-13\'-OH and α-13\'-COOH, only a few studies on the function of these α-LCM have been performed. Work so far focused on anti-proliferative effects, modulation of inflammatory processes and modulation of lipid homeostasis. Our group described anti-proliferative effects of the α-LCM due to pro-apoptotic action [@bib20]. In HepG2 cells, the α-LCM induced cleavage of caspases 3, 7 and 9 as well as PARP-1 and induced mitochondrial dysfunction as characterized by reduced mitochondrial membrane potential and induced intra-mitochondrial ROS formation. The anti-proliferative effect of α-13\'-COOH was shown also in murine glioma C6 cancer cells [@bib19]. Others have reported that the α-LCM interfere with inflammatory processes by modulating activity of COX1 and COX2 and consequently by blocking production of PGE~2~[@bib18]. Recent work by our group focused on the effects of the α-LCM on macrophage foam cell formation [@bib17]. We have shown that α-LCM induce expression of the scavenger receptor CD36, the major receptor responsible for oxLDL uptake, in human macrophages, in contrast to the inhibiting actions of α-TOH [@bib17]. Despite up-regulation of CD36, uptake of oxLDL and oxLDL-induced lipid accumulation was reduced in human macrophages, similar to the effects of α-TOH on oxLDL-mediated foam cell formation. An important finding of this recent study was that the metabolite α-13\'-COOH was detected in serum providing for the first time evidence for the bioavailability of the α-LCM outside the liver. Another key finding of the study was that bioactivity of the α-LCM occur at lower concentrations and with mechanisms distinct from those of α-TOH. Taken together, these recent studies provide evidence for a role of the α-LCM as signaling molecules derived metabolically from α-TOH.](gr4){#f0020}
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